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Background: Expected treatment effectiveness from
medications can be diminished due to suboptimal ad-
herence. Medication nonadherence has been linked to
pill burden from the quantity of medications; however,
medication regimens with similar quantities of medica-
tions vary in complexity due to multiple dosage forms,
frequency of dosing, and additional usage directions.
Thus, a simple medication count ignores medication
regimen complexity, especially as it pertains to a pa-
tient-level perspective that includes prescription and
over-the-counter medications. A gap exists in the study
of a patient-level medication regimen complexity met-
ric across disease-specific populations.
Objective: The goal of this study was to implement
the quantitative Medication Regimen Complexity In-
dex (MRCI) at the patient level in defined populations
with chronic disease (geriatric depression, HIV, diabe-
tes mellitus, and hypertension). Patient-level medica-
tion regimen complexity included all prescribed medi-
cations and over-the-counter medications documented
in the electronic medication list.
Methods: Using electronic medical records at the
University of Colorado Hospital ambulatory clinics,
we sampled 4 retrospective cohorts of adult patients
in active care in 2011 with a qualifying medical di-
agnosis and prescribed disease-specific medication.
Samples were randomly selected from all qualifying
patients; de-identified information was coded using
the MRCI.
April 2013Results: Cohort-defining disease-specific prescription
medications (eg, antidepressants for the depression-de-
fined cohort) contributed20% to the total patient-level
complexityMRCI score; theMRCI score was dominated
by complexity associated with all other prescription medi-
cations.Withindisease-specificcohorts,MRCIscoresdiffer-
entiated patients with the highest and lowest medication
counts, comorbidity counts, and the Charlson comorbidity
index scores. For example, geriatric depression patients had
a highest quartile mean MRCI score of 41 and a lowest
quartile mean MRCI score of 13. Between disease-specific
cohorts, high and low MRCI scores differed because each
cohort had its own MRCI ranges. For example, highest
quartileMRCIscoresvaried fromameanMRCIscoreof41
(geriatric depression) to 30 (hypertension); lowest quartile
scores ranged from ameanMRCI score of 7 (hypertension
andHIV) to 13 (geriatric depression).
Conclusions: MRCI components of dosing fre-
quency and prescribed medications outside of the co-
hort-defining disease medications contributed the most
to the patient-level scores. Thus, chronic disease man-
agement programs may want to consider all medica-
tions that patients are taking and examine ways to
reduce complexity, such as reducing multiple dosing
frequencies when possible. MRCI scores differentiated
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Clinical Therapeutics
Chigh and low patient-level complexity measures, rep-
resenting possible utility as a prospective tool to iden-
tify target patients for intervention. Future work in-
cludes simplifying the MRCI and enhancing the scores
with medication risk factors, as well as explicitly link-
ing to adherence and health services. (Clin Ther. 2013;
35:385–398)
2013 Elsevier HS Journals, Inc.
Key words: chronic disease, comorbidities, diabe-
es, geriatric depression, HIV, hypertension, medica-
ion regimen complexity, MRCI.
NTRODUCTION
he importance of appropriate medication use in the
anagement of chronic diseases has been widely exam-
ned.1–4Medication adherence is influenced bymany fac-
ors, including some individual factors (eg, socioeco-
omic status, age, sex, race) and some health system
actors (eg, health literacy, convenience of pharmacy,
edication regimen complexity).5,6 Medication regimen
omplexity is modifiable in health systems and can be
easured electronically without direct data collection
rompatients.A recent literature review found strong and
onsistent evidence that increases in dosing frequency
nd medication regimen complexity (eg, multiple medi-
ations, multiple doses, specific dietary or time require-
ents) were related to poor medication adherence in pa-
ients with hypertension as measured by using blood
ressure control.6 Patients with other chronic diseases
ace population-specific issues with medication complex-
ty and adherence as well.7–14
Empirical studies have provided compelling evi-
ence that increases in dosing frequency and medica-
ion regimen complexity are related to decreases in
edication adherence and subsequent decreased treat-
ent effectiveness.1–5,15–19 A simple, common mea-
ure of medication regimen complexity is a count of
rescribed medications. However, medication count is
nlikely to be an adequate measure of regimen com-
lexity because it does not address other regimen char-
cteristics contributing to complexity, such as dosage
orms, dosing frequencies, and usage directions. In ad-
ition, medication count may not include over-the-
ounter (OTC) medications, which in some patients
an contribute greatly to medication complexity.
It is unknown as to whether medication regimen
omplexity can be characterized by distinct empirical
Open access under 
C BY-NC-ND license. istributions for defined clinical populations. In addi-
386ion, the relationship between medication regimen
omplexity and medication count is not well estab-
ished because patients taking either a few or many
edications could have equally high medication com-
lexity. The current study addresses these knowledge
aps in medication regimen complexity measurement.
For this study, medication regimen complexity was
ssessed by using a validatedmeasurement tool called the
edication Regimen Complexity Index (MRCI), a 65-
tem instrument that can be completed with data from
atient medical records by using electronic script infor-
ation in amedication list.20Complexity levels are based
on weighted averages of the number of drugs, dosage
frequency, administration instructions, and prescribed
dosage forms. Gaps exist in empirical studies of MRCI:
most MRCI studies measuring medication regimen com-
plexity are limited to the treatment regimen for the
chronic disease, ignoring all other medications for co-
morbidities and symptoms of other health problems,
both prescribed and OTC21–31; the medication regimen
omplexity literature uses general metrics such as the
RCI and also highly tailored metrics for complexity
uch as one specifically for epilepsy or the Antiviral Reg-
men Complexity Index, thus preventing comparison of
edication regimen complexity across disease states32–
6; and finally there is no empirical association with
MRCI scores and other objective metrics of patient or
medication complexity thatwould demonstrate the tool’s
external validity for patients in real-world settings. The
current article addresses all of these gaps.
The 3 objectives of this study were to: (1) compare
patient-level MRCI scores (including prescription and
OTC medications) across 4 defined chronic disease–de-
fined prevalent cohorts; (2) examine contributions of
types of medications (prescription medication specific to
the cohort-defining disease state, other prescription med-
ications, andOTCmedications) andmedication regimen
characteristics (dosage form, dosing frequency, and addi-
tional usage directions) with total patient-level MRCI
scores; and (3) measure the relationship of MRCI scores
with objective metrics of patient severity or disease com-
plexity such as medication count, diagnosis count, and
Charlson comorbidity index scores.
METHODS
This was a cross-sectional, retrospective study of dis-
tinct patient cohorts performed by using existing med-
ical record data. The prevalent cohorts comprised
adult ambulatory patients diagnosed with hyperten-
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A.M. Libby et al.sion, diabetes, HIV, or geriatric depression. These dis-
ease states were chosen based on a desire for variation
across cohorts in medication complexity of disease
state medications (a priori assumption of high medica-
tion complexity for HIV and diabetes, and low com-
plexity for depression); expected high chronic disease
comorbidity would suggest additional medications
outside of the cohort-defining disease state.
Data Source
We accessed the electronic health care records of the
University of Colorado Anschutz Medical Campus
(CU-AMC) University Hospital ambulatory clinics to
obtain anonymous records on retrospective cohorts of
active patients aged 19 to 89 years in treatment for 4
defined chronic diseases. Information on the medica-
tion list and current comorbidity list was extracted for
the latest visit recorded between July 1, 2011, and De-
cember 31, 2011. We defined disease-specific cohorts
of active patients in the health system with any set of
comorbidities or active medications (ie, there were no
exclusions due to comorbidities). To qualify for entry
into a disease state cohort, each patient needed a dis-
ease state diagnosis (and diagnostic code) and 1 ac-
tive medication from the class of drugs indicated as
therapy for that disease (defined later for each cohort).
At least 1 prescription medication had to be given on
the medication list for patients with that cohort-defin-
ing disease; for example, antidepressants were used for
the geriatric depression cohort. In this example, anti-
depressants were referred to as “disease state medica-
tions,” and all other prescription medications were re-
ferred to as “other prescription medications.” All
medications available without a prescription were re-
ferred to as “OTC medications.” To qualify as an ac-
tive patient in addition to the qualifying index visit, the
patient needed at least 1 additional clinic visit for any
reason in the year 2011.
Among the patients who qualified for inclusion, we
used a random number generator and routine to elec-
tronically select each cohort. The primary outcome
measures were the patient-level and disease-specific
(hypertension, diabetes, geriatric depression, or HIV)
MRCI scores. A sample size of 87 subjects per group
was needed to test the difference in MRCI between
patients in the 2 groups, assuming a 2-sided test of
significance,   0.05, 90% power, and mean (SD)
RCI score of 15 (10) for hypertension and mean
RCI score of 21 (14) for diabetes, as examples. We
April 2013hus selected 100 patients in each population subgroup
o facilitate comparisons. For these 100 patients, infor-
ation from the current medication list was extracted
lectronically from the electronic health record system
nd de-identified. The CU-AMC clinics have electronic
ealth record systems with a clinical data repository
anaged by a third party (QED Clinical, Inc. dba
INA, Dallas, Texas). The study protocol was ap-
roved by the Colorado Multiple Institutional Review
oard (COMIRB #11-0980).
MRCI Coding
Using the published MRCI tool, we developed a
Microsoft Access Database for coding. A screen shot is
available in the Supplemental Appendix in the online
version at http://dx.doi.org/10.1016/j.clinthera.2013.
02.019. This tool allowed uniform forms for 3 separate
codes of medication regimen complexity: for disease-
specific prescription medications (eg, antiretrovirals
for the HIV cohort), nondisease-specific prescription
medications (eg, all other prescription medications
that were not antiretrovirals for the HIV cohort), and
OTCmedications. Built-in reports allowed pharmacist
coders to conduct quality checks during coding. Pa-
tients were given a unique cohort-specific identifier,
and their medication list was coded by a clinical phar-
macist. Random samples of 30 patients within each
cohort were coded by a different pharmacist rather
than the primary coder to assess interrater reliability.
Before coding, the study team coded case examples
together in a group meeting, discussed definitions and
rationale, and made decision rules for cases not clearly
addressed in the tool instructions, such as when to code
a medication as prescription versus OTC in cases in
which the medication can be obtained from either
source. There wasminimal and nonsignificant variabil-
ity between primary and secondary pharmacist raters.
Weighted  statistics between coders 1 and 2 for each
cohort were as follows: geriatric, 0.9387; HIV, 0.9307;
diabetes, 0.8457; and hypertension, 0.9396.
Data Analysis
Coded patient-level data were extracted from the
Access tool for management and analysis by using SAS
software (SAS Institute, Inc, Cary, North Carolina).
Descriptive statistics were used to compare MRCI
scores within and between chronic disease cohorts. Us-
ing the Duncan multiple comparison test, we were able
to identify statistically significant differences in the
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Clinical TherapeuticsMRCI score between the cohorts and within eachmed-
ication type (eg, disease-specific cohort-defining pre-
scription medications, other prescription medications,
OTC medications). The variable specification was re-
formatted when possible to conduct sensitivity tests by
using Bonferroni coefficients and Duncan and Tukey
distributions. Multiple linear regression was used to
assess the bivariate relationships between medication
regimen complexity and other objective metrics of pa-
tient complexity. The a priori level of significance was
set at P  0.05.
Population of Inference
The cohorts are representative of patients enrolled
in active care in the CU-AMC clinics. The geriatric
depression cohort was selected from the Seniors Clinic
for adults aged 70 years and was coded by Drs.
Vande Griend and Linnebur; the HIV cohort was se-
lected from the Infectious Disease Clinic and was
coded by Dr. Fish; and the diabetes and hypertension
cohorts were selected from the Family Medicine or
General Internal Medicine Clinics and were coded by
Dr. Saseen. Secondary coders were Dr. Metz and Ms.
Vu. The patients were enrolled in the clinic with private
or public health insurance and were seeking primary
care at a university-based academic medical center that
also has clinical pharmacy services.
Chronic Disease Cohorts
Cohorts were defined by using the following diag-
nostic codes (International Classification of Diseases,
Ninth Revision [ICD-9]) on the “current problem list”
in the electronic health record in concordance with
prescription records for any and all medications in the
associated drug class identified by using National Drug
Codes or name within the associated General Product
Index (GPI) group; both codes had to be present at the
index visit among qualified active patients (as de-
scribed in the following text). There was no direct mea-
sure of whether the medication was being taken, only
that it was recorded as prescribed or continued at the
index visit. The presence of a diagnosed comorbidity
that would have qualified for another cohort was not a
basis for exclusion; for example, patients who qualified
for entry into the diabetes cohort were not excluded
if they had also been treated for hypertension or
depression. m
388Geriatric Depression
Treated with at least 1 antidepressant in the GPI 58
Antidepressant Class and ICD-9 code 296.2, 296.3,
300.4, or 311.
HIV
Treated with at least 1 antiretroviral in GPI 12 An-
tiviral Class and ICD-9 code 795.71, 042, or V08.
Diabetes Mellitus
Treated with at least 1 antidiabetic agent as defined
by GPI 27 and ICD-9 code 250.x.
Hypertension
Treated with at least 1 antihypertensive as defined
by GPI 36 and either blood pressure 140/90 mm Hg
or ICD-9 code 401.xx.
Measures
Dependent Variable
The original validatedMRCI tool was developed by
George et al20 to assign complexity scores to the med-
cation regimen of individual patients based on medi-
ation dosage forms, dosing frequencies, and addi-
ional administration instructions (eg, take at a
pecified time, take in relation to food). The MRCI is
omposed of 3 separate sections: (1) dosage forms; (2)
osing frequency; and (3) additional directions. The
otal MRCI score is equal to the simple sum of the
eighted scores of all 3 sections. The MRCI tool is a
eighted sum with a “base case” weight of 1 given to
each) the dosage form of a tablet/capsule and a dosing
requency of once daily. Other dosage forms and dos-
ng frequencies are assigned increasing weightings re-
ated to the increasing difficulty in administration (eg,
njectable agents). Additional directions attached to a
edication per the patient electronic medical record
lso add to the score and are weighted according to
ifficultly in administration. The weighted MRCI was
alidated by using concordance with clinician judg-
ent of medication regimen complexity. In this study,
e calculated MRCI scores for 3 medication types per
atient: prescription disease-state medications, pre-
cription medications for other nondisease medica-
ions, and OTC medications. Additional directions
ere coded if theywere included in the script (eg, break
r crush, take with food) but would not reflect instruc-
ions in a medication’s package insert. The patient-
evel MRCI is the sum of these 3 scores. These are
easured in aggregate and also in quartiles.
Volume 35 Number 4
s
m
h
d
t
m
h
a
m
a
2
C
t
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For demographic variables, the following items
were collected from the CU-AMC clinics patient health
record on the index visit date. Sex was measured as
male or female as a categorical count variable, and age
was a continuous variable measured in years.
Comorbidities were measured by using the vali-
dated Charlson comorbidity index,37 a weighted aver-
age of a count of 17 individual ICD-9–coded chronic
diseases listed as “current comorbidities” on the index
date, including the primary cohort disease. The un-
weighted frequency of Charlson comorbidities was
also reported, as HIV has a high weight. Because 1 of
our cohorts was HIV, this fact dramatically changed
the relative Charlson comorbidity index scores of the 4
cohorts, and we therefore present both forms of the
index.We also provide a simple count of the number of
unique diagnosis codes in the “current comorbidity”
list on the index date. These are measured in aggregate
and also as quartiles.
Medication counts were measured as continuous
variables defined by counting the medications on the
electronic medication list, subgrouped according to
medication type (prescription disease, prescription
nondisease, and OTC). A named medication on the list
was not included in the medication count if the listed
medication was missing both a dose and frequency.
Disease-specific medications were prescriptionmed-
ications defined by using the First DataBank/Red Book
databases according to GPI code, National Drug
Codes, and product and generic name. For depression,
this included antidepressant drug classes according to
GPI grouper; for HIV, this included antiretrovirals; for
diabetes, this included antidiabetic agents; and for hy-
pertension, this included the following drug classes:
angiotensin-converting enzyme inhibitors, angioten-
sin-receptor blockers, diuretics, calcium channel
blockers, -blockers, and -blockers. These lists were
elected by the clinical authors. In a case in which a
edication was listed twice in the patient’s electronic
ealth record with the same formulation but a different
ose (eg, warfarin 5 mg and warfarin 2 mg), it was
reated as 1 medication.
Nondisease medications were all other prescription
edications excluding the medications captured as co-
ort-defining disease-specific medications.
OTC medications were defined as medications
vailable without a prescription. In the event that a
edication (same dosage form and same dose) was
April 2013vailable via prescription or OTC, such as omeprazole
0 mg, the medication was coded as OTC. Facts &
omparisons Online was used to determine prescrip-
ion/OTC status.38
Polypharmacy was measured as a categorical vari-
able (1–5 medications, 6–10 medications, and 11
medications) based on all medications on the active
medication list.
RESULTS
Population characteristics for the 4 disease state co-
horts were compared (Table I). Compared with the
clinic population from which each cohort was ran-
domly selected, the age and sex distribution was simi-
lar for each cohort (n 100). As expected, the geriatric
depression cohort was older and mostly female, con-
trasted with the HIV cohort, which was younger and
mostlymale. The total medication count in each cohort
varied fairly widely within cohorts, with a minimum of
1 by definition and as high as 27 in the HIV cohort.
Except for the hypertension cohort, the categorical
subset of patients taking11 medications represented
the largest percentage of the population (geriatric de-
pression, 58%; HIV, 48%; diabetes, 47%; and hyper-
tension, 28%). Geriatric depression patients had the
highest mean total medications per patient at 12.1
(range, 3–26), followed by HIV with 10.8 (range,
1–27) and diabetes with 10.4 (range, 2–25); hyperten-
sion had the lowest mean per patient with 8.3 (range,
2–18). Disease-specific medications were limited, with
a low of 1.2 in the geriatric depression cohort and a
high of 2.3 in theHIV cohort. Themedication type that
represented the greatest number in every cohort was
the nondisease-specific prescriptions.
Figure 1 presents the cohort-specific mean patient-
level MRCI with medication type contribution: disease-
specific prescriptions, nondisease prescriptions, andOTC
medications. The patient-levelMRCI score for the hyper-
tension cohort (mean [SD], 17.80 [9.13]) was signifi-
cantly lower than the mean scores for the other cohorts
(geriatric depression, 25.44 [11.67]; HIV, 21.76 [12.49];
diabetes, 22.98 [11.58]; P  0.05). Nondisease-specific
prescriptions represented the majority of the total pa-
tient-level MRCI scores for all cohorts at approximately
two thirds (Table II). For the geriatric depression cohort,
the contribution of OTC medications (25%) to the total
MRCI score was larger than that of disease-specific pre-
scription medications (12%); in the other cohorts, this
finding was reversed.
389
Clinical TherapeuticsTable II shows decomposed MRCI scores within
medication type. The mean total patient-level MRCI in
the geriatric depression cohort was 25.44 (range, 6–64).
This was the highest average patient-level MRCI com-
paredwith the other cohorts. The diabetes cohort had the
next highest mean patient-level MRCI (22.98; range,
4–65.5) followed by theHIV (21.76; range, 2–67.5) and
hypertension (17.8; range, 3–46) cohorts. The patient-
level MRCI for the hypertension cohort was significantly
lower than each of the other 3 groups (P  0.05). The
disease-specific MRCI scores for the HIV and diabetes
cohorts were significantly higher than the other 2 groups.
The OTCMRCI for the geriatric depression cohort was
significantly higher than each of the other 3 groups. The
medication type subscores were further decomposed into
MRCI section A/dosage form, section B/dosing fre-
quency, and section C/additional directions. Across all
cohorts, dosing frequency contributed the largest portion
of the total patient-level MRCI score.
Table III shows components and relative contribu-
tions of MRCI scores by assessing deviations from the
base case conditions in the weighting scheme. In MRCI
sections A and B (dosage form and dosing frequency,
Table I. Population characteristics: chronic disease c
Geriatric Depression
Clinic Cohort Cli
Defined current disease and
medications 276 100 14
Demographic characteristics
Age, mean, y 80.8 81.3 5
Sex (% female) 78 79 1
Clinical characteristics
Charlson Index* 2.0 (0–7)
No. of medications, mean (SD) 12.1 (3–26)
By medication type
No. of disease-specific
medications (cohort-
defining) 1.2 (1–3)
No. of other medications 7.4 (1–19)
No. of OTC medications 3.5 (0–12)
Categorical
% on 1–5 medications (total) 4
% on 6–10 medications (total) 38
% on 11 medications 58
OTC  over-the-counter.
*Of 17 Charlson comorbidity index groups, excluding primary cohorespectively), the base case takes a weight of 1. In section
390A, only about one quarter of patients across cohorts had
only the base case dosage form (tablet/capsule). A sub-
stantial proportion of each cohort had at least 3 dosage
forms representing 41%, 20%, 47%, and 39% in the
geriatric depression, HIV, diabetes, and hypertension co-
horts, respectively. Compared with the base case in sec-
tion B (once-daily dosing frequency), again there was a
low percentage of patients who had only the frequency of
once-daily dosing. A majority of each cohort had at least
3 different dosing frequencies (geriatric depression, 75%;
HIV, 66%; diabetes, 69%; and hypertension, 56%). In
section C of the MRCI, a preponderance of each cohort
had at least 1 additional direction for use (78%–97%),
with a substantial portion of the patients with at least 3
additional directions for use. Across all cohorts, section
B/dosing frequency contributed the most complexity
points to the MRCI score (55%–64%), followed by sec-
tion A/dosage form.
Table IV illustrates quartile descriptive statistics and
interquartile comparisons for patient-level MRCI scores
and also for 3 established metrics of medical complexity:
medication count, Charlson comorbidity index, and the
count of current medical problems. In each cohort, mean
s.
HIV Diabetes Mellitus Hypertension
Cohort Clinic Cohort Clinic Cohort
100 1730 100 5790 100
49.1 60.8 59.6 62.9 64.3
18 53 51 55 46
1.9 (1–4) 2.2 (1–7) 1.2 (0–5)
10.8 (1–27) 10.4 (2–25) 8.3 (2–18)
2.3 (1–6) 1.9 (1–4) 2.1 (1–5)
7.6 (0–23) 6.8 (0–18) 4.7 (0–12)
1.0 (0–5) 1.7 (0–11) 1.5 (0–7)
19 15 30
33 38 42
48 47 28
ase; unweighted frequencies.ohort
nic
0
0.1
7
rt diseMRCI scores differed significantly among quartiles. Sig-
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A.M. Libby et al.nificant differences in mean medication count and count
of comorbidities were also detected between high and
low MRCI quartiles. Both weighted and unweighted
Charlson comorbidity index scores revealed significant
differentiationbetweenhigh and lowMRCIquartiles; the
middle 2 quartiles did not differ significantly from each
other as uniformly as the first and fourth quartiles. With-
out exception, all cohorts’ 3medical complexity variables
increase monotonically with each increasing quartile of
their MRCI score.
DISCUSSION
Themean total patient-levelMRCIwas greatest for the
geriatric depression cohort, followed by the diabetes,
HIV, and hypertension cohorts. Across all cohorts, the
majority of patient-level MRCI scores was attributable
to “other” prescriptionmedications distinct and differ-
ent from disease-specific cohort-defining prescription
medications and not due to medication regimen com-
plexity from the cohort-defining disease-specific medi-
cations. Patient-level MRCI seemed to differentiate be-
tween high, medium, and low medical complexity as
determined by other established measures of medical
complexity. The absoluteMRCI values for meeting com-
plexity thresholds differed by cohort (eg, low-complexity
geriatric depression had a mean of 13 compared with
hypertension, which had a mean of 7; high-complexity
30
25
20
15
10
5
Geriatric
Depression
HIV Diabetes Hypertension
0
M
R
C
I S
co
re
OTC
Other prescriptions
Disease-specific prescriptions
Figure. Average patient-level Medication Regimen
Complexity Index (MRCI): contribution to
MRCI score according to medication type.geriatric depression had a mean of 41, compared with t
April 2013hypertension, which had a mean of 30). The added med-
ication regimen complexity beyond the cohort-defining
prescription medications highlights the limitations of
published medication complexity scores that only mea-
sure medications for 1 indication.
This study identified noteworthy additional findings
from each defined cohort. Patients represented in the
geriatric depression cohort had high rates of polyphar-
macy. For example, geriatric depression patients aver-
aged 12.1 medications (range, 3–26). Part of this was
due to the high percentage of OTC medication use,
which also contributed greatly to the overallMRCI score
(25% of the score vs 8% for HIV, 12% for diabetes, and
14%for hypertension). This finding illustrates the impor-
tance of evaluating OTC medication use in the geriatric
patient and accurately documenting it in the record.OTC
medications have the potential to contribute significantly
to overall complexity, which potentially translates into
increased difficultly with adherence.
The MRCI tool has several potential clinical appli-
cations for the geriatric population, but more research
is needed. Targeting medication complexity with the
goal of simplifying a patient’s regimen may be an ap-
propriate clinical intervention (eg, changing a patient
from a TID drug to a once-daily drug). However, it is
also unknown if reducing medication complexity has
positive effects on clinically relevant health care out-
comes such as adherence, overall health, and hospital-
ization. Financial burden associated with medications
is also not accounted for in theMRCI, and the geriatric
population is often highly sensitive to medication cost
given their high averagemedication count and frequent
reliance on a fixed income.
With respect to the HIV patients, we expected that
their HIV-specific regimens would be fairly burden-
some and complex, and also that the patients would be
treated for other chronic and aging-related conditions.
However, significant changes in the management of
patients with HIV infection have occurred over the
past decade. Because virologic response to antiretrovi-
ral therapies is closely linked to patient adherence,39 an
mportant recent trend has been to improve adherence
hrough the use of combination products containing 2,
, or 4 different antiretroviral agents. Use of these com-
ination products has substantially reduced antiretro-
iral pill burdens and simplified treatment regimens for
oth patients and providers.40 However, it must also
e recognized that important safety issues exist related
o the potential for adverse drug reactions and drug
391
Table II. Cohort medication regimen characteristics.
Characteristic
Geriatric Depression
(n  100)
HIV
(n  100)
Diabetes Mellitus
(n  100)
Hypertension
(n  100)
Mean (SD) Range (IQR) Mean (SD) Range (IQR) Mean (SD) Range (IQR) Mean (SD) Range (IQR)
MRCI, total per patient 25.44 (11.67) 6–64* (18–†30.5) 21.76 (12.49) 2–67.5 (11.75–29.0)†,‡ 22.98 (11.58) 4–65.5 (14.25–30.25)† 17.80 (9.13) 3–46 (11–24)*‡,§
Medication count 12.10 (4.89) 3–26 (9–15) 10.8 (5.85) 1–27 (6–13) 10.41 (5.05) 2–25 (6–13) 8.32 (3.75) 2–18 (5–11)
MRCI sections (weighted)
A/dosage form 6.87 (4.17) 2–21 (3–9) 4.71 (3.14) 1–22 (2–6.5) 7.04 (3.79) 1–16 (4–9) 5.92 (3.87) 1–19 (3–8)
B/dosing frequency 14.46 (6.95) 2–39 (9.5–18) 13.99 (8.66) 1–41.5 (7–20.75) 12.89 (7.57) 2–42.5 (8–16.75) 9.83 (5.32) 1–28 (6–12.25)
C/additional directions 4.11 (2.61) 0–12 (2–5) 3.06 (2.47) 0–10 (1–4.5) 3.05 (2.55) 0–13 (1–4) 2.05 (1.76) 0–8 (1–3)
MRCI, disease-specific drugs
(% of total)
3.03 (1.12) 2–6.5 (2–4)*,§ 4.92 (2.12) 2–12 (3–6)*,‡,§ 6.28 (3.10) 1–15 (4–8.5)*,†,‡ 3.52 (1.47) 2–9 (2–4)*,§
11.91% 22.61% 27.33% 19.76%
Medication count 1.19 (0.42) 1–3 (1–1) 2.33 (1.04) 1–6 (2–3) 1.93 (0.81) 1–4 (1–2) 2.06 (1.03) 1–5 (1–3)
A/dosage form 1.00 (0.00) 1–1 (1–1) 1.07 (0.41) 1–4 (1–1) 2.46 (2.02) 0–8 (1–4) 0.99 (0.1) 0–1 (1–1)
B/dosing frequency 1.18 (0.42) 1–3 (1–1) 3.36 (1.80) 1–9 (2–4) 2.91 (1.62) 1–11 (2–4) 2.18 (1.18) 1–6 (1–3)
C/additional directions 0.85 (0.91) 0–4 (0–1) 0.49 (0.66) 0–3 (0–1) 0.91 (1.02) 0–4 (0–2) 0.35 (0.66) 0–3 (0–1)
MRCI, other prescriptions
(% of total)
16.00 (9.57) 2–46.5 (9.5–20.5)† 15.04 (11.17) 0–61.5 (6.25–22)† 13.92 (9.38) 0–43.5 (6.25–19) 11.73 (8.04) 0–39 (6.25–16.75)*,‡
62.89% 69.12% 60.57% 65.90%
Medication count 7.38 (3.67) 1–19 (5–9.5) 7.51 (5.15) 0–23 (3.5–10) 6.81 (3.85) 0–18 (3.5–9) 4.73 (2.96) 0–12 (2–7)
A/dosage form 4.24 (3.54) 1–19 (1–5.5) 3.00 (2.93) 0–20 (1–5) 3.68 (3.22) 0–13 (1–5) 4.04 (3.64) 0–17 (1–6)
B/dosing frequency 9.37 (5.88) 0–31.5 (5–12.5) 9.63 (7.74) 0–34.5 (3.5–14.25) 8.28 (5.92) 0–25.5 (4–10.5) 6.15 (4.62) 0–24 (2.5–8.25)
C/additional directions 2.39 (1.86) 0–8 (1–4) 2.41 (2.17) 0–9 (1–4) 1.96 (2.11) 0–10 (0–3) 1.54 (1.47) 0–7 (0–2)
MRCI, OTC
(% of total)
6.41 (4.71) 0–25.5 (3–9)*,‡,§ 1.80 (2.38) 0–10 (0–3)‡ 2.79 (3.61) 0–15 (0–5)‡ 2.55 (2.94) 0–15.5 (0–4)‡
25.20% 8.27% 12.14% 14.33%
Medication count 3.53 (2.60) 0–12 (1–5) 0.96 (1.21) 0–5 (0–2) 1.67 (2.02) 0–11 (0–3) 1.53 (1.64) 0–7 (0–2)
A/dosage form 1.63 (1.40) 0–7 (1–3) 0.64 (0.90) 0–5 (0–1) 0.90 (1.15) 0–6 (0–1) 0.89 (1.04) 0–5 (0–1)
B/dosing frequency 3.91 (3.38) 0–19.5 (1–6) 1.00 (1.60) 0–7 (0–1) 1.71 (2.60) 0–14 (0–2) 1.50 (1.98) 0–10.5 (0–2)
C/additional directions 0.87 (1.15) 0–5 (0–1) 0.16 (0.49) 0–2 (0–0) 0.18 (0.63) 0–3 (0–0) 0.16 (0.49) 0–2 (0–0)
IQR  interquartile range; MRCI Medication Regimen Complexity Index; OTC  over-the-counter.
*Statistically different from the HIV cohort.
†Statistically different from hypertension cohort.
‡Statistically different from the geriatric depression cohort.
§Statistically different from the diabetes mellitus cohort.
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A.M. Libby et al.interactions inherent in the administration of multiple-
drug antiretroviral regimens. These issues are presently
unaccounted for in the MRCI. Although the current
study demonstrated that calculated medication com-
plexity scores may be significantly reduced through the
use of combination products, the overall risks associ-
ated with multiple-medication regimens have not been
greatly affected clinically.
Another important change related to management
of HIV infection is that, along with increased survival,
management of other chronic diseases such as hyper-
tension, dyslipidemias, and diabetes has become an
important part of overall patient management. The
current study found that HIV-specific medications ac-
counted for an average of only 22% of medication
complexity scores whereas other prescription medica-
tions accounted for another 69% of the total scores. It
Table III. Cohort medication regimen sensitivity.
Characteristic
Geriatric De
(n  1
MRCI, total patient-level 25.44 (1
MRCI section A/dosage form
No. of unique dosage forms 2.58 (1
Frequency, tablet/capsule only 27
Frequency, tablet/capsule  1 other form 32
Frequency, tablet/capsule  2 forms 17
Frequency, tablet/capsule  3 or more
forms 24
Section A/% contribution to MRCI 27
MRCI section B/dose frequency
No. of unique dose frequency 10.52 (4
Frequency, once daily only 7
Frequency, once daily  1 dose frequency 18
Frequency, once daily  2 dose
frequencies 31
Frequency, once daily  3 dose
frequencies 44
Section B/% contribution to MRCI 57
MRCI section C/additional directions
No. of additional direction items 4.08 (2
Frequency, 1 additional direction only 17
Frequency, 2 additional directions 37
Frequency, 3 or more additional
directions 43
Section C/% contribution to MRCI 16
Values are given as mean (SD) or %. MRCIMedication Reis possible that the potential for increased adherence to
April 2013antiretroviral medications may not be fully realized
because the concomitant management of other acute and
chronic diseases contributes to a high complexity of the
overall medication regimen. Although OTCmedications
did not contribute as much to complexity scores in the
HIV cohort (8%) compared with other cohorts (12%–
25%), it is nevertheless important to account for this
added complexity in this group of patients as well.
The hypertension cohort represents patients with a
well-recognized, major independent medication com-
plexity score; the global health impact of this disease is
staggering considering that cardiovascular disease
is the leading cause of death in the United States.41
In addition, hypertension is common among the
adult population aged 20 years, and these patients
had complex regimens with double-digit complexity
scores, indicating the potential need for regimen sim-
on HIV
(n  100)
Diabetes Mellitus
(n  100)
Hypertension
(n  100)
21.76 (12.49) 22.98 (11.58) 17.80 (9.13)
1.84 (1.01) 2.58 (1.30) 2.27 (1.29)
45 24 36
35 29 25
14 19 24
6 28 15
22 31 33
9.29 (5.20) 8.72 (4.56) 7.20 (3.34)
5 6 16
29 25 28
14 30 26
52 39 30
64 56 55
3.05 (2.47) 3.02 (2.51) 2.03 (1.74)
20 20 31
36 34 30
30 32 17
14 13 12
Complexity Index.pressi
00)
1.67)
.54)
.32)
.59)
gimenplification. High adherence with antihypertensive drug
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Clinical Therapeuticstherapy has been associated with a lower risk of car-
diovascular events.4 If a medication complexity tool
ould identify complex regimens and result in clinical
nterventions that improve adherence (eg, something
s simple as using fixed-dose combination antihyper-
ensive products42), then improved adherence should
esult in overall clinical benefits.
In terms of patients with diabetes, the diabetes-specific
RCI scores were among the highest of the 4 cohort-
efining disease-specific scores. This finding reflects that
hese patients have disease state regimens that contain
edications for glycemic control which have features
hat increase complexity such as varying dosage forms,
osing frequencies, and additional directions.43 The pres-
ence of diabetes, regardless of other comorbidities, in-
Table IV. Quartile comparisons across measures of m
Quartile
Geriatric Depression
Cohort
Quartile 1 (low MRCI score) 13.06 (6–18)*,†,‡ 7
Medication count 7.16 (2.12)*,†,‡ 4
Charlson score (unweighted) 1.32 (1.22)†,‡ 1
Charlson score (weighted) 1.84 (1.75)†,‡ 6
Medically coded problem
count 20.16 (6.68)†,‡ 10
Quartile 2 (medium-low MRCI
score) 20.36 (18–24)†,‡,§ 15
Medication count 10.92 (2.64)‡,§ 8
Charlson score (unweighted) 1.64 (1.29)‡ 1
Charlson score (weighted) 2.28 (1.81)‡ 6
Medically coded problem
count 22.68 (9.52)‡ 16
Quartile 3 (medium-high MRCI
score) 27.14 (24–30)*,‡,§ 24
Medication count 12.52 (3.06)‡,§ 11
Charlson score (Unweighted) 2.20 (1.44)§ 2
Charlson score (Weighted) 2.84 (2.39)§ 7
Medically coded problem
count 27.24 (9.42)‡,§ 17
Quartile 4 (highest MRCI
score) 41.18 (31–64)*,†,§ 38
Medication count 17.80 (4.12)*,†,§ 18
Charlson score (Unweighted) 2.76 (1.92)*,§ 2
Charlson score (Weighted) 3.64 (2.77)*,§ 7
Medically coded problem
count 32.20 (11.14)*,§ 27
Values are given as mean (range OR SD). MRCI Medication Regi
*Significant difference from quartile 2 by using Duncan test.
†Significant difference from quartile 3 by using Duncan test.
‡Significant difference from quartile 4 by using Duncan test.
§Significant difference from quartile 1 by using Duncan test.creases the patient’s medical complexity and medication
394complexity. Control of glycemia and complications in
diabetes has been shown to reduce the risk of morbidity.
If highmedication complexity is identified andoptimized,
it is reasonable to speculate that resultant improvedmed-
ication adherence would improve health outcomes. Pa-
tients with diabetes in our study had the highest number
of dosage forms, which highlights their unique chal-
lenges. Moreover, because of the risk of hypoglycemia
with certain medications used to treat hyperglycemia (ie,
insulin), the medication complexity of patients with dia-
betes would increase if risk was incorporated in our tool.
Limitations of the current study include the potential
for inaccurate medication record lists and diagnosis lists.
These issues have been acknowledged as a limitation of
using other indices for patient complexity such as the
ation or medical complexity.
Cohort
Diabetes Mellitus
Cohort Hypertension Cohort
–11.5)*,†,‡ 10.08 (4–14)*,†,‡ 7.30 (3–11)*,†,‡
.83)*,†,‡ 5.20 (2.58)*,†,‡ 4.24 (1.83)*,†,‡
.63)†,‡ 1.44 (0.77)*,†,‡ 0.80 (1.00)‡
.82)†,‡ 1.64 (1.19)*,†,‡ 1.00 (1.35)‡
.48)*,†,‡ 17.12 (7.47)†,‡ 14.96 (8.22)†,‡
2–19.5)†,‡,§ 18.16 (14.5–22)†,‡,§ 13.84 (11–16)†,‡,§
.35)†,‡,§ 8.60 (2.29)†,‡,§ 7.04 (1.81)†,‡,§
.91)†,‡ 2.16 (1.03)§ 0.80 (0.96)‡
.33)‡ 2.84 (1.60)§ 1.16 (1.46)‡
.49)‡,§ 20.92 (9.98)‡ 20.60 (10.00)‡
0–29)*,‡,§ 24.66 (x–y)*,‡,§ 19.78 (16.5–24)*,‡,§
.08)*,‡,§ 11.12 (1.92)*,‡,§ 9.76 (2.31)*,‡,§
.00)*,§ 2.52 (1.05)§ 1.28 (1.24)‡
.45)§ 3.24 (1.64)§ 1.64 (1.78)‡
.85)‡,§ 24.72 (14.20)‡,§ 25.64 (10.41)‡,§
9–67.5)*,†,§ 39.02 (31–65.5)*,†,§ 30.28 (24–46)*,†,§
.24)*,†,§ 16.72 (3.98)*,†,§ 12.24 (2.99)*,†,§
.13)*,§ 2.52 (1.33)§ 1.88 (1.42)*,§
.06)*,§ 3.16 (2.01)§ 2.36 (1.85)*,§
.50)*,†,§ 36.08 (13.72)*,†,§ 29.16 (15.88)*,§
omplexity Index.edic
HIV
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men CCharlson comorbidity index.37 However, the calculated
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ications without a dose or directions were not counted in
the calculation. This was a limitation of a recent study of
hard-codedMRCI scores (as opposed to hand-scoring by
pharmacists) from electronic medical records in a large
sample (N 89,645) of older adults in a postacute home
care setting.44 Written and verbal usage instructions that
were not in the electronic script could not be observed or
coded, making these features undercounted in theMRCI
scores. For regimens that have high complexity in this
regard, such as certain renal dosing or sensitive pharma-
cokinetics/pharmacodynamics reflected in additional in-
structions, the MRCI score is an underestimate. Another
limitation of our study design was case selection from
among patients with coded diagnoses (potentially miss-
ing patients who are among the qualifying patients but
who have not been diagnosed). This case selection will
also exclude diagnosed patients not treated with first-line
pharmacotherapy (potentiallymissingqualifyingmedica-
tions due to nondrug therapies or due to use of off-label
or second-line pharmacotherapies) and will exclude
treated anddiagnosedpatientswhodonot have 2 visits to
the clinic in the previous year (and thus are not considered
as patients in active care).
In addition, the current study did not use direct mea-
sures of adherence proxies, such as filled prescriptions, as
the medical record documented prescriptions written but
not necessarily filled at a pharmacy. As health care sys-
temswith electronic health records, such as theUniversity
of Colorado ambulatory clinics, linkwith pharmacy ben-
efit management and health care claims data sources,
more comprehensive health services research will be pos-
sible for patients in community-based nonintegrated
health care settings. MRCI scores linked to clinical and
system outcomes can support future health care research.
Nevertheless, this study represents a real-world applica-
tion of the MRCI tool to the electronic medical record.
A limitation of theMRCI toolmay be in theweighting
of factors uniformly across all populations versus higher
weights for some features. For example, there is no score
for medications dosed infrequently such as those dosed
once weekly or once monthly in theMRCI. In the geriat-
ric population, in whom osteoporosis medications are
frequently dosed onceweekly and vitaminDandB12may
be dosed once monthly, the current MRCI calculation
would not account for these common medications. In
addition, higher weighting may be necessary for in-
creased difficulty in remembering infrequently dosed
medications. Higher weighting might also be needed for
April 2013MRCI factors such as medications that require good vi-
sion (eg, injections) or those that requiremanual dexterity
(eg, topical products or eye drops), which could also con-
tribute more highly to complexity. This is an area for
improvement in the tool.
To determine the value of the MRCI as a tool for
identifying patients in need of intervention for adher-
ence, more empirical evidence is needed linking the 2
constructs. To date, only 2 studies have reported a
relationship between higher MRCI scores and poorer
medication adherence: 1 for geriatric patients (N 
212) recently discharged from the hospital and another
for a large sample (N  94,860) of outpatients with
iabetes.30,45 There are additional gaps in knowledge
related to the link between MRCI and adherence. It is
not known if medication complexity and a patient’s
ability to adhere to a medication regimen is a linear
relationship. It is possible that adherence is good until
a certain threshold of complexity is reached, then
drops drastically when complexity increases further
with the addition of more medication or the alteration
of a dosing regimen. It is also not known if the adher-
ence risk versus benefit of adding a medication to a
patient’s regimen is altered depending on the patient’s
baseline complexity. It is possible that adding a medi-
cation to a low-complexity regimen is worth the risk,
but that adding that same medication to an already
highly complex regimen is not worth the risk. The
MRCI itself could also be simplified, as several items
contributed only a tiny portion of variation to the total
score and might be productively dropped from the cal-
culation with no loss in predictive validity. These are
issues for future work. Despite these gaps, a patient-
level medication regimen complexity index that can be
used across chronic disease populations may be very
useful to future clinical pharmacy practices. The tool
that was used in this study can be used to streamline
clinical care by identifying therapeutically complex pa-
tients for pharmacist intervention.
CONCLUSIONS
This study illustrated that dosing frequency is an im-
portant component of medication complexity, as is a
variety of dosage forms. Prescriptions for other reasons
in addition to targeted disease-state treatment was the
other major feature of medication regimen complexity.
Thus, alternative medication complexity metrics must
be able to account for all of these features across all of
a patient’s medications to have valuable and accurate
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Clinical Therapeuticsinformation about medication regimen complexity.
Patient-level medication regimen complexity can then
be linked to health care service utilization, cost, inpa-
tient and emergency department visits, and medication
adherence; clinical outcomes such as markers for dis-
ease control such as blood pressure or lipids; and
health-related quality of life and health utility.
MRCI advancements could contribute to national
health policy in the United States, as the health care
reform legislation calls for planned approaches to op-
timize medication regimens and provide comprehen-
sive medication reviews. The gap in our ability to mea-
sure medication complexity makes such a planned
approach very difficult. These tools could contribute to
the American Society of Health-System Pharmacists’
Pharmacy Practice Model Initiative, which described
an optimal pharmacy practice model as 1 in which
“pharmacist-provided drug therapy management
should be prioritized using a patient medication com-
plexity index” in recommendation B-11.46
ACKNOWLEDGMENTS
This study was funded by The ALSAM Foundation
Skaggs Scholars Program grant at the University of
Colorado Skaggs School of Pharmacy and Pharmaceu-
tical Sciences.
We gratefully acknowledge input from participants
at the September 2012 Skaggs Biomedical Symposium
in Aurora, Colorado.
Dr. Libby was responsible for the literature search,
study design, data analysis, data interpretation, and
writing of the manuscript. Dr. Fish was responsible for
the literature search, study design , data collection/cod-
ing, data interpretation, and writing of the manuscript.
Mr. Hosokawa was responsible for the data analysis,
data interpretation, and writing of the manuscript. Dr.
Linnebur was responsible for the literature search,
study design , data collection/coding, data interpreta-
tion, and writing of the manuscript. Metz was respon-
sible for the literature search, data collection/coding,
data interpretation, and writing of the manuscript. Dr.
Nair was responsible for the study design, data inter-
pretation, and writing of the manuscript. Dr. Saseen
was responsible for the literature search, study design ,
data collection/coding, data interpretation, and writ-
ing of the manuscript. Dr. Vande Griend was respon-
sible for the literature search, study design, data collec-
tion/coding, data interpretation, and writing of the
manuscript. Ms. Vu was responsible for the literature
396search, data collection/coding, data interpretation, and
writing of the manuscript. Dr. Hirsch was responsible
for the literature search, study design, data interpreta-
tion, and writing of the manuscript.
CONFLICTS OF INTEREST
Dr. Libby has received funding from the Agency for
HealthCare Research and Quality (AHRQ), National
Institute of Mental Health (NIMH), NIHOffice of Re-
search on Women’s Health (ORWH). Dr. Fish has re-
ceived funding from Pfizer, Hospira. Dr. Hirsch has
received funding from Novartis Pharmaceuticals. Dr.
Saseen has received funding from Daiichi-Sankyo, Inc,
The Colorado Health Foundation, Takeda Pharma-
ceuticals International, Inc., U.S. DHHS, Heath Re-
sources and Services Administration. Dr. Linnebur has
received funding from the National Institute on Aging
(NIA) and Eli Lilly Co. Dr. Nair has received funding
from Takeda, Daiichi Sankyo, Janssen. Dr. Vande
Griend, Dr.Metz,Mr. Hosokawa, andMs. Vu have no
conflicts of interest to report.
SUPPLEMENTARY MATERIAL
Supplemental appendix accompanying this article can be
found in the online version at http://dx.doi.org/10.1016/j.
clinthera.2013.02.019.
REFERENCES
1. Dragomir A, Cote R, Roy L, et al. Impact of adherence to
antihypertensive agents on clinical outcomes and hospital-
ization costs.Med Care. 2010;48:418–425.
2. Krousel-WoodM, Islam T,Muntner P, et al. Association of
depression with antihypertensive medication adherence in
older adults: cross-sectional and longitudinal findings from
CoSMO.Ann BehavMed. 2010;40:248–257.
3. May HT, Sheng X, Catinella AP, et al. Antilipidemic
adherence post-coronary artery disease diagnosis among
those with and without an ICD-9 diagnosis of depression.
J Psychos Res. 2010;69:169–174.
4. Mazzaglia G, Ambrosioni E, AlacquaM, et al. Adherence to
antihypertensive medications and cardiovascular morbid-
ity among newly diagnosed hypertensive patients. Circula-
tion. 2009;120:1598–1605.
5. McLean DL, McAlister FA, Johnson JA, et al. A randomized
trial of the effect of community pharmacist and nurse care
on improving blood pressure management in patients with
diabetes mellitus: study of cardiovascular risk intervention
by pharmacists-hypertension (SCRIP-HTN). Arch Intern
Med. 2008;168:2355–2361.
Volume 35 Number 4
11
1
1
1
1
A.M. Libby et al.6. Carter BL, BergusGR,Dawson JD, et
al. A cluster randomized trial to
evaluate physician/pharmacist col-
laboration to improve blood pres-
sure control. J ClinHyperten. 2008;10:
260–271.
7. Bhatt DL, Scheiman J, Abraham NS,
et al. ACCF/ACG/AHA 2008 expert
consensus document on reducing
thegastrointestinal risksof antiplate-
let therapy and NSAID use: a report
of the American College of Cardiol-
ogy Foundation Task Force on Clini-
cal Expert Consensus Documents.
J Am Coll Cardiol. 2008;52:1502–
1517.
8. Blanco F, San Román J, Vispo E, et
al. Management of metabolic com-
plications and cardiovascular risk in
HIV-infected patients. AIDS Review.
2010;12:231–241.
9. FeigenbaumK, Longstaff L.Manage-
ment of the metabolic syndrome in
patients with human immunodefi-
ciency virus. Diabetes Educ. 2010;36:
457–464.
0. Gopal M, Bhaskaran A, Khalife W,
Barbagelata A. Heart disease in pa-
tients with HIV/AIDS—an emerging
clinical problem. Curr Cardiol Rev.
2009;5:149–154.
1. Kaul S, Bolger AF, Herrington D, et
al. Thiazolidinedione drugs and car-
diovascular risks: a science advisory
from the American Heart Associa-
tion andAmericanCollegeOfCardi-
ology Foundation. J Am Coll Cardiol.
2010;55:1885–1894.
2. Osborn CY, Cavanaugh K, Wallston
KA, et al. Diabetes numeracy: an
overlooked factor in understanding
racial disparities in glycemic control.
Diabetes Care. 2009;32:1614–1619.
3. Schillinger D, Grumbach K, Piette J,
et al. Association of health literacy
with diabetes outcomes. JAMA.
2002;288:475–482.
4. Wiysonge CS, Bradley H, Mayosi
BM, et al. Beta-blockers for hyper-
tension. Cochrane Database Syst Rev.
2007;1:CD002003.
5. Ingersoll KS, Cohen J. The impact of
medication regimen factors on ad-
April 2013herence to chronic treatment: a
review of literature. J Behav Med.
2008;31:213–224.
16. Morisky DE, Ang A, Krousel-Wood
M, Ward HJ. Predictive validity of a
medication adherence measure in
an outpatient setting. J Clin Hyperten.
2008;10:348–354.
17. Lewin G. Medication therapy man-
agement services: a critical review.
J Am Pharm Assoc. 2005;45:580–
587.
18. Berry SD, Quach L, Procter-Gray E,
et al. Poor adherence to medica-
tions may be associated with falls. J
Gerontol A Biol Sci Med Sci. 2010;65:
553–558.
19. MaA,ChenDM,ChauFM, Saberi P.
Improving adherence and clinical
outcomes through an HIV pharma-
cist’s interventions.AIDSCare. 2010;
22:1189–1194.
20. George J, Phun YT, Bailey MJ, et al.
Development and validation of the
medication regimen complexity in-
dex. Ann Pharmacother. 2004;38:
1369–1376.
21. Pollack M, Chastek B, Williams SA.
“PDB36 Impact of Treatment Com-
plexity on Adherence and Glycemic
Control: An Analysis of Oral Anti-
DiabeticAgents.”ValueHealth. 2009;
3:A103.
22. Cardone KE,Manley HJ, GrabeDW,
et al. Quantifying home medication
regimen changes and quality of life
in patients receiving nocturnal home
hemodialysis.Hemodial Int. 2011;15:
234–242.
23. Correr CJ,Melchiors AC, Fernandez-
Llimos F, Pontarolo R. Effects of a
pharmacotherapy follow-up in com-
munity pharmacies on type 2 diabe-
tes patients in Brazil. Int J Clin Pharm.
2011;33:273–280.
24. Hayes KS. Adding medications in
the emergency department: effect
on knowledge of medications in
older adults. J Emerg Med. 1999;
25:178–182.
25. Farris KD, Kelly MW, Tryon J. Clock
drawing test and medication com-
plexity index as indicators ofmedica-tion management capacity: a pilot
study. J Am Pharm Assoc (Wash).
2003;43:78–81.
26. Melchiors AC, Correr CJ, Fernandez-
Llimos F. Translation and validation
into Portuguese language of the
medication regimen complexity in-
dex. Arq Bras Cardiol. 2007;89:210–
218.
27. Barnason S, Zimmerman L, Hertzog
M, Schulz P. Pilot testing of a medi-
cation self-management transition
intervention for heart failure pa-
tients.West JNursRes. 2010;32:849–
870.
28. Frohlich SE, Zaccolo AV, da Silva SL,
Mengue SS. Association between
drugprescribing andquality of life in
primary care. PharmWorld Sci. 2010;
32:744–751.
29. Dierich MT, Mueller C, Westra BL.
Medication regimens in older home
care patients. J Gerontol Nurs. 2011;
37:45–55.
30. Mansur N, Weiss A, Beloosesky Y.
Lookingbeyondpolypharmacy:quan-
tificationofmedication regimencom-
plexity in the elderly. Am J Geriatr
Pharmacother. 2012;10:223–229.
31. Stange D, Kriston L, Langebrake C,
et al. Development and psychomet-
ric evaluation of the German version
of the Medication Regimen Com-
plexity Index (MRCI-D). J Eval Clin
Pract. 2012;18:515–522.
32. DiIorio C, McDonnell M, McCarty
F, Yeager K. Initial testing of the
Antiretroviral Medication Complex-
ity Index. J Assoc Nurses AIDS Care.
2006;17:26–36.
33. DiIorio C, Yeager K, Shafer PO, et al.
The epilepsy medication and treat-
ment complexity index: reliability
and validity testing. J Neurosci Nurs.
2003;35:155–162.
34. Ferrari CM, Castro LH, Settervall CH,
et al. Validity and reliability of the
Portuguese version of the Epilepsy
MedicationTreatmentComplexity In-
dex for Brazil. Epilepsy Behav. 2011;
21:467–472.
35. Martin S, Wolters PL, Calabrese SK,
et al. The Antiretroviral Regimen
397
44
4
4
4
control: an analysis of oral antidia-
4
e40–e41.
Clinical TherapeuticsComplexity Index. A novel method
of quantifying regimen complexity. J
Acquir Immune Defic Syndr. 2007;
45:535–544.
36. Yeager KA, Diiorio C, Shafer PO, et
al. The complexity of treatments for
persons with epilepsy. Epilepsy Behav.
2005;7:679–686.
37. Charlson M, Szatrowski TP, Peter-
son J, Gold J. Validation of a com-
bined comorbidity index. J Clin Epide-
miol. 1994;47:1245–1251.
38. Wolters Kluwer Health. Facts & Com-
parisons eAnswers. http://online.fact
sandcomparisons.com. Accessed Au-
gust10,2012.
39. Thompson MA, Mugavero MJ,
Amico KR, et al. Guidelines for im-
proving entry into and retention in
care and antiretroviral adherence
for persons with HIV: evidence-
based recommendations from an
International Association of Physi-
cians in AIDS Care panel. Ann Intern
Med. 2012;156:817–833, W-284,
W-285, W-286, W-287, W-288,
W-289, W-290, W-291, W-292,
W-293,W-294.
40. Llibre JM, Clotet B. Once-daily
single-tablet regimens: a long and
winding road to excellence in antiret-
roviral treatment. AIDS Reviews.
2012;14:168–178.
1. Roger VL, Go AS, Lloyd-Jones DM,
et al.Heart disease and stroke statis-
tics—2012update: a report from the
AmericanHeartAssociation.Circula-
tion. 2012;125:e2–e220.
2. Gupta AK, Arshad S, Poulter NR.
Compliance, safety, and effective-
ness of fixed-dose combinations of
antihypertensive agents: a meta-
analysis.Hypertension. 2010;55:399–
407.
3. Nichols GA, Kimes TM, Harp JB, et
al. Glycemic response and attain-
ment of A1C goals following newly
initiated insulin therapy for type 2
diabetes. Diabetes Care. 2012;35:
495–497.44.
4. McDonald MV, Peng TR, Sridharan
S, et al. Automating the medication
regimen complexity index. J Am Med
398Inform Assoc. 2012 Dec 25. [Epub
ahead of print].
5. Pollack M, Chastek B, Williams S,
Moran J. Impact of treatment com-
plexity on adherence and glycemicC-238, Aurora, CO 80045. E-mail: annbetic agents. J Clin Outcomes Manag.
2010;17:257–265.
6. Cobaugh DJ. Advancing pharmacy
practice models: Achieving consen-
sus.Am JHealth-Syst Pharm. 2011;68:Address correspondence to: Anne M. Libby, PhD, Department of Clinical
Pharmacy and Center for Pharmaceutical Outcomes Research, Skaggs
School of Pharmacy and Pharmaceutical Sciences, University of Colorado
Anschutz Medical Campus, 12850 E. Montview Boulevard, Campus Boxe.libby@ucdenver.edu
Volume 35 Number 4
A.M. Libby et al.Supplemental Appendix Figure. Screenshot of the d
coding. Available f
colleges/pharmacy/Ratabase tool for Medication Regimen Complexity Index
or download at http://www.ucdenver.edu/academics/
esearch/researchareas/Pages/researchareas.aspx.April 2013 398.e1
